THNPY yields 2.21% · PFE yields 6.20%● Live data
📍 THNPY pulled ahead of the other in Year 1
Combined, THNPY + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of THNPY + PFE for your $10,000?
Technip Energies N.V., together with its subsidiaries, operates as an engineering and technology company for the energy transition in Europe, Russia, the Asia Pacific, Africa, the Middle East, and the Americas. The company operates through two segments, Projects Delivery, and Technology, Products and Services. It is involved in the engineering, procurement, construction management, commissioning, and transport and installation of various energy projects. The company also engages in designing, engineering, procurement, construction, and project management of various onshore and offshore facilities related to gas monetization, ethylene, hydrogen, refining, and chemical processing from biofuels and hydrocarbons. In addition, it develops, designs, commercializes, and integrates a range of technologies in gas monetization, refining, petrochemicals, and fertilizers, hydrogen, and sustainable chemistry; provides land and marine-based loading and transfer systems services to the oil and gas, petrochemical, chemical, and decarbonization industries; and offers a range of project management consulting services to the energy industry. Further, it offers robotics, asset monitoring, and surveillance solutions, as well as nondestructive testing and material testing solutions for harsh environments of a range of industries, such as nuclear, oil and gas, offshore wind, or aerospace; commercializes a complete solution for inspection, and maintenance and repair for its proprietary software supervision Cyxense Commander, which is used to remotely control an heterogeneous fleet of robots; develops a range of proprietary third party robots; and provides digital services. Technip Energies N.V. was incorporated in 2019 and is headquartered in Nanterre, France.
Full THNPY Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.